Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 20/20 | 0.57 |
| ▸ | PSEN2 | P49810 | 20/20 | 0.57 |
| ▸ | APH1B | Q8WW43 | 20/20 | 0.57 |
| ▸ | NCSTN | Q92542 | 20/20 | 0.57 |
| ▸ | APH1A | Q96BI3 | 20/20 | 0.57 |
| ▸ | PSENEN | Q9NZ42 | 20/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2359573 | 0.84 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8070672 | 0.79 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3795011 | 0.79 | PSEN1 (0.64) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4102615 | 0.79 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12738729 | 0.78 | PSEN1 (0.60) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7739011 | 0.77 | PSEN1 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4103642 | 0.77 | PSEN1 (0.66) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4090982 | 0.77 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL16685699 | 0.76 | PSEN1 (0.75) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8817778 | 0.75 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288403-B2 | Heterocyclic gamma secretase modulators | HOFFMANN-LA ROCHE INC. (US) | 2012-10-16 | — | — | US | claimed |
| EP-2355817-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-08-17 | — | — | EP | claimed |
| WO-2010052199-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-14 | — | — | WO | claimed |
| US-20100120874-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | HOFFMANN-LA ROCHE, INC. | 2010-05-13 | — | — | US | claimed |
| US-8288403-B2 | Heterocyclic gamma secretase modulators | HOFFMANN-LA ROCHE INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288403-B2 | Heterocyclic gamma secretase modulators | HOFFMANN-LA ROCHE INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288403-B2 | Heterocyclic gamma secretase modulators | HOFFMANN-LA ROCHE INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2355817-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010052199-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120874-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | HOFFMANN-LA ROCHE, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20100120874-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | HOFFMANN-LA ROCHE, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20100120874-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | HOFFMANN-LA ROCHE, INC. | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120874-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | BACE1, APH1A, APP | PSEN1 5/4885PSEN2 7/4885APH1B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.